Please use this identifier to cite or link to this item:
https://doi.org/10.1186/gm388
| Title: | Predicting cancer drivers: are we there yet? | Authors: | Krishnan, V.G Ng, P.C |
Keywords: | B Raf kinase cetuximab panitumumab protein p53 cancer cell cancer research cancer therapy cell cycle colorectal cancer cost driver mutation drug sensitivity gene function gene mutation gene product gene sequence genetic correlation genetic variability germ line human loss of function mutation melanoma metastasis missense mutation neoplasm note nucleic acid base substitution oncogene K ras passenger mutation point mutation prediction priority journal protein function scientist single nucleotide polymorphism somatic mutation treatment outcome tumor growth |
Issue Date: | 2012 | Citation: | Krishnan, V.G, Ng, P.C (2012). Predicting cancer drivers: are we there yet?. Genome Medicine 4 (11) : 88. ScholarBank@NUS Repository. https://doi.org/10.1186/gm388 | Rights: | Attribution 4.0 International | Abstract: | Genomic variants with a key role in causing cancer or affecting the response to cancertherapeutics need to be identified so that they can be targeted for therapy. The transFIC tool aimsto identify somatic point mutations that drive cancer in sequencing projects. This package isavailable as a web service, a stand-alone program and a website. It improves the functionalprediction scores generated by popular established prediction tools and will be useful to cancerresearchers.See research article: http://genomemedicine.com/content/4/11/89. © 2012 BioMed Central Ltd. | Source Title: | Genome Medicine | URI: | https://scholarbank.nus.edu.sg/handle/10635/181841 | ISSN: | 1756994X | DOI: | 10.1186/gm388 | Rights: | Attribution 4.0 International |
| Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
| File | Description | Size | Format | Access Settings | Version | |
|---|---|---|---|---|---|---|
| 10_1186_gm388.pdf | 135.65 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License
